Literature DB >> 24946698

Rhabdomyolysis: review of the literature.

R Zutt1, A J van der Kooi2, G E Linthorst3, R J A Wanders4, M de Visser5.   

Abstract

Rhabdomyolysis is a serious and potentially life threatening condition. Although consensus criteria for rhabdomyolysis is lacking, a reasonable definition is elevation of serum creatine kinase activity of at least 10 times the upper limit of normal followed by a rapid decrease of the sCK level to (near) normal values. The clinical presentation can vary widely, classical features are myalgia, weakness and pigmenturia. However, this classic triad is seen in less than 10% of patients. Acute renal failure due to acute tubular necrosis as a result of mechanical obstruction by myoglobin is the most common complication, in particular if sCK is >16.000 IU/l, which may be as high as 100,000 IU/l. Mortality rate is approximately 10% and significantly higher in patients with acute renal failure. Timely recognition of rhabdomyolysis is key for treatment. In the acute phase, treatment should be aimed at preserving renal function, resolving compartment syndrome, restoring metabolic derangements, and volume replacement. Most patients experience only one episode of rhabdomyolysis, mostly by substance abuse, medication, trauma or epileptic seizures. In case of recurrent rhabdomyolysis, a history of exercise intolerance or a positive family history for neuromuscular disorders, further investigations are needed to identify the underlying, often genetic, disorder. We propose a diagnostic algorithm for use in clinical practice.
Copyright © 2014 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Myoglobinuria; Rhabdomyolysis

Mesh:

Year:  2014        PMID: 24946698     DOI: 10.1016/j.nmd.2014.05.005

Source DB:  PubMed          Journal:  Neuromuscul Disord        ISSN: 0960-8966            Impact factor:   4.296


  91 in total

1.  Cumulative incidence and risk factors of creatine kinase elevation associated with telbivudine.

Authors:  Li Chen; Cai Cheng; Bicui Chen; Yue Zhao; Jiming Zhang; Bin Wang
Journal:  Eur J Clin Pharmacol       Date:  2015-11-14       Impact factor: 2.953

2.  [(Very) high Creatinkinase concentration after exertional whole-body electromyostimulation application: health risks and longitudinal adaptations].

Authors:  Wolfgang Kemmler; Marc Teschler; Michael Bebenek; Simon von Stengel
Journal:  Wien Med Wochenschr       Date:  2015-10-26

3.  Clinical features of Haff disease and myositis after the consumption of boiled brackish water crayfish: a retrospective study of 96 cases at a single centre.

Authors:  Fei He; Jun Ni; Jun-Ai Huang; Yao Liu; Chao Wu; Jun Wang
Journal:  Intern Emerg Med       Date:  2018-05-08       Impact factor: 3.397

4.  [Weakness of the extremities in a 73-year-old male patient].

Authors:  M Attaran-Bandarabadi; P Kalbasi Anaraki; W Gwinner; H Haller
Journal:  Internist (Berl)       Date:  2016-08       Impact factor: 0.743

5.  Rhabdomyolysis observed at forensic autopsy: a series of 52 cases.

Authors:  Hsuan-Yun Hu; Shyh-Yuh Wei; Chih-Hsin Pan
Journal:  Forensic Sci Med Pathol       Date:  2018-07-28       Impact factor: 2.007

6.  Paracetamol use and lowered risk of acute kidney injury in patients with rhabdomyolysis.

Authors:  Maxime Desgrouas; Thierry Boulain
Journal:  J Nephrol       Date:  2021-01-05       Impact factor: 3.902

7.  COVID-19 infection and severe rhabdomyolysis.

Authors:  Vishal Patel; Bashar Alzghoul; Saminder Singh Kalra
Journal:  Proc (Bayl Univ Med Cent)       Date:  2021-03-23

8.  Levetiracetam-induced rhabdomyolysis: the first Italian case.

Authors:  Eugenia Rota; Luciano Arena; Lorenzo Celli; Lucia Testa; Nicola Morelli
Journal:  Neurol Sci       Date:  2018-04-26       Impact factor: 3.307

9.  Rhabdomyolysis in Stuve-Wiedemann syndrome.

Authors:  Pemantah Sandheeah Ramdeny; Colin Powell; Mallinath Chakraborty; Louise Hartley
Journal:  BMJ Case Rep       Date:  2018-02-08

10.  An Unusual Presentation of Rhabdomyolysis in a Newly Diagnosed Sjögren's Syndrome Associated Polymyositis.

Authors:  Shanti Virupannavar; Suncica Volkov
Journal:  Arch Rheumatol       Date:  2016-04-20       Impact factor: 1.472

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.